The DOI matches its Crossref record.
Clinical Pharmacokinetics of Morphine
Abstract
Morphine (M) is recommended by the World Health Organization as the treatment of choice for moderate-to-severe cancer pain. Development of sensitive radioimmunoassays (RIA) and high-performance liquid chromatography in the past 20 years has allowed study of the pharmacokinetics of M, which remain incompletely understood. Data derived by RIA must be interpreted with caution due to cross-reactivity with anti-sera by metabolites, impairing assay specificity. The pharmacokinetics of M have been determined for various clinical situations, but there is large interpatient variability for most parameters. M is readily absorbed from all routes of administration, except transdermal, and it can be injected spinally. Peak plasma levels are achieved within 15-20 min of intramuscular and subcutaneous administration, and within 30-90 min after oral. Peak levels after oral administration are much lower than after parenteral routes, since oral M undergoes extensive first-pass metabolism in the liver. With repeated administration, the oral-parenteral relative potency ratio is 1:3 M can be administered epidurally or intrathecally and has also been given intracerebroventricularly. Epidural M enters the subarachnoid space, but is also absorbed into the systemic circulation. Only 5% of a dose crosses the dura. M administered in the lumbar region is quickly redistributed in the cerebrospinal fluid in a rostral direction, explaining the high incidence of systemic side effects following spinal administration. After absorption, M is rapidly and widely distributed and crosses the blood-brain barrier. With therapeutic doses, plasma protein binding is only 20-35%, and the volume of distribution is 1-6 L/kg. The primary site of M metabolism is the liver, and the dose should be reduced in patients with liver disease. Glucuronidation is the main metabolic pathway, but the principal metabolite, morphine-3-glucuronide (M3G), is inactive. Morphine-6-glucuronide (M6G) is produced in smaller amounts than M3G, but is pharmacologically active and many times more potent than M. The ratio of M6G to M in plasma, after a dose of M, is approximately 10:1, and the ratio does not change with increasing doses or prolonged treatment. Normorphine (NM) is also active, and is formed to a greater extent after oral administration; it is not, however, usually found in plasma. NM may be neurotoxic. M and its metabolites are excreted by the kidney, but urinary free M accounts for less than 10% of an administered dose. In patients with renal insufficiency, the metabolites accumulate, though M itself is still excreted.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Morphine and alternative opioids in cancer pain: the EAPC recommendations
Hanks, G. W., Conno, F. D., Cherny, N., Hanna, M., Kalso, E., McQuay, H. J., Mercadante, S., Meynadier, J., Poulain, P., Ripamonti, C., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1680 · Cited by 862
Pergolizzi, J., Böger, R. H., Budd, K., Dahan, A., Erdine, S., Hans, G., Kress, H., Langford, R., Likar, R., Raffa, R. B., et al. (2008) · Pain Practice · doi:10.1111/j.1533-2500.2008.00204.x · Cited by 854
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Zhao, Y. H., Le, J., Abraham, M. H., Hersey, A., Eddershaw, P. J., Luscombe, C. N., Boutina, D., Beck, G., Sherborne, B., Cooper, I., et al. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1031 · Cited by 526
Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief
Campa, D., Gioia, A., Tomei, A., Poli, P., & Barale, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100385 · Cited by 345
Metadata
- Authors
- Glare, P. A., & Walsh, T. D.
- Venue
- Therapeutic Drug Monitoring
- Published
- 1991-01
- Volume
- 13
- Issue
- 1
- Pages
- 1-23
- ISSN
- 0163-4356 (ISSN-L)
- OpenAlex
- W2017974394
- Cited by
- 290
- References
- 0
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics of Morphine. https://app.cochat.ai/papers/10.1097/00007691-199101000-00001
- The paper
- Glare, P. A., & Walsh, T. D. (1991). Clinical Pharmacokinetics of Morphine. Therapeutic Drug Monitoring. https://doi.org/10.1097/00007691-199101000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.